J&J: acquisres Yellow Jersey for $1.25bn
(CercleFinance.com) - Johnson & Johnson has announced the acquisition of Yellow Jersey, a subsidiary of Numab Therapeutics, for approximately $1.
25 billion, in order to secure worldwide rights to NM26, a novel bispecific antibody.
NM26, ready for Phase 2 studies in atopic dermatitis (AD), is aimed at two targets involved in skin inflammation and itching.
AD, the most common inflammatory skin disease, causes itching, inflammation and can lead to serious complications.
Johnson & Johnson aims to improve treatments for patients, the majority of whom do not find remission with current therapies, by investing in bispecific antibodies like NM26.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
25 billion, in order to secure worldwide rights to NM26, a novel bispecific antibody.
NM26, ready for Phase 2 studies in atopic dermatitis (AD), is aimed at two targets involved in skin inflammation and itching.
AD, the most common inflammatory skin disease, causes itching, inflammation and can lead to serious complications.
Johnson & Johnson aims to improve treatments for patients, the majority of whom do not find remission with current therapies, by investing in bispecific antibodies like NM26.
Copyright (c) 2024 CercleFinance.com. All rights reserved.